Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a purine analog for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

Abstract: Disclosed herein is a method for treating cancer with DNA-hypomethylating agents. Also disclosed herein is a method of selecting a treatment for a subject. Treatment can be given to a subject for more than one cycle of treatment to obtain improved efficacy of the treatment.

Abstract: The present invention relates to antisense oligonucleotides that are able to induce the skipping of an aberrant 128 nucleotide exon from human CEP290 pre-mRNA and vectors expressing such oligonucleotide.

Abstract: The invention relates to the diagnostic and therapeutic uses of a miRNA molecule, an equivalent or a source thereof in a neuronal deficiency or a disease and condition associated with neuronal deficiency.

Abstract: A method of inhibiting the expression of ghrelin in a cell, method comprising introducing to the cell an RNAi, the RNAi comprising a sense strand and an antisense strand, the antisense strand comprising any of SEQ ID NO: 1 to SEQ ID NO: 42, and the sense strand being complementary to the antisense strand. Also, a method of inhibiting the expression of ghrelin o-acyltransferase in a cell, the method comprising introducing to the cell an RNAi, the RNAi comprising a sense strand and an antisense strand, the antisense strand comprising any of SEQ ID NO: 43 to SEQ ID NO: 68, and the sense strand being complementary to the antisense strand.

Abstract: Described herein are methods of reducing, preventing, or reducing the risk of, an adverse effect of a pathogen using a glycan preparation. In some embodiments, the pathogen is a drug resistant pathogen.

Abstract: Provided is a solubilization enhancer for pyrroloquinoline quinone or a salt thereof in an aqueous solvent, comprising resistant dextrin as an active ingredient.

Abstract: A medication is disclosed, and the medication includes carboxymethylated starch. The medication includes a citrate and/or citric acid for reducing postoperative adhesions. The citrate and/or citric acid is/are situated on the surface of granules of the starch, and includes 1 to 20 percent by weight of citrate and/or citric acid relative to the starch.

Abstract: Disclosed herein are pharmaceutical salts of a cationic protonated polyamine pharmaceutical agent and an anionic organic carboxylate which is hydrophobic when in protonated form, particularly suited for oral administration, where these salts have good bioavailability in solid dosage forms and may be used in the treatment of cancer and other medical conditions for which the pharmaceutical agent is intended.

Abstract: The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided.

Abstract: An integrated hydrogen gas generator with hydrogen water module comprises a water tank, an electrolytic module, an integrated flow channel device, a humidifying module, and a hydrogen water module. The electrolytic module is configured to electrolyze the water in the water tank to generate a gas comprising hydrogen. The water tank, the humidifying module, and the hydrogen water module are respectively coupled to the integrated passageway module so that the water and the gas comprising hydrogen flow in a special sequence between them. The humidifying module is configured to humidify the gas comprising hydrogen. The hydrogen water module is configured for accommodating liquid and receiving the gas comprising hydrogen into the liquid to form a liquid comprising hydrogen. The configuration of pipeline is replaced by the integrated passageway module in the integrated hydrogen gas generator of the present invention.

Abstract: Compositions, methods of manufacturing compositions, methods of protecting against respiratory problems including coronavirus and coronavirus-associated severe acute respiratory syndrome (SARS) in humans and animals, are provided. Compositions comprising inorganic nitrate used for improving nitric oxide levels, improving health and/or reducing symptoms of SARS are provided. The compositions and methods are applicable for subjects experiencing SARS, and for protecting non-infected subjects against SARS. Compositions and methods for improving nitric oxide levels in a subject disclosed herein comprise administration of compositions comprising inorganic nitrate such as potassium nitrate or sodium nitrate optionally combined with ascorbate.

Abstract: An ophthalmic emulsion for ocular delivery of antioxidants comprising one or more antioxidants, at least one oil of vegetable, mineral or animal origin, at least one surfactant and at least one pharmaceutically acceptable excipient, for effective management of Age Related Macular Degenaration (ARMD) and its subsequent clinical manifestations and complications.

Abstract: The invention relates to method of treating chronic inflammatory diseases in subjects in need thereof by administering calcium lactate as an active agent. The calcium lactate can be provided in a pharmaceutical, food, or nutrient composition.

Abstract: A method for promoting lipid metabolism or assisting in body weight control is disclosed, which includes: administering a composition to a subject in need thereof. The composition includes: a trivalent chromium complex being a complex of a trivalent chromium compound and a lactoferrin; and taurine or a derivative thereof.

Abstract: Disclosed herein are platelet-like particles incorporating antimicrobial metallic nanoparticles. The platelet-like particles include an ultra-low crosslinked polymeric microgel and fibrin targeting moiety. The antimicrobial metallic nanoparticles can be covalently or noncovalently incorporated into the platelet-like particles. The particles are useful to stop bleeding and to promote wound healing while at the same time suppressing bacterial infections that can accompany tissue damage.

Abstract: The present technology relates to film forming compositions comprising antimicrobial agents, as well as to methods of inhibiting bacterial growth, controlling the rate of release of an antimicrobial agent from a film forming polymer, coating a medical device, rendering the inner lumen of a medical device biofilm resistant, and treating a human or animal.

Abstract: Compositions and methods for protecting bees from toxins and for preventing or decreasing colony collapse are provided. The compositions comprise carbon microparticles which, when ingested by bees, increase their survival after exposure to toxins such as pesticides.

Abstract: A versatile carrier system for systemic delivery of oncolytic viruses comprises dendritic cells having at least one oncolytic virus loaded therein. It is believed that the dendritic cells will protect the oncolytic virus(es) against neutralizing antibodies, can transport the oncolytic virus(es) to targeted tumor locations, and then deliver virions to the tumor locations.

Abstract: Methods and compositions are provided for treating a subject for aging-associated conditions, e.g., cognitive impairment conditions. Aspects of the methods include administering a young plasma-comprising blood product to an individual in need thereof, e.g., an individual suffering from or at risk of developing the aging-associated condition, e.g., aging-associated cognitive impairment. Also provided are compositions and kits thereof that find use in practicing methods of the invention.

Abstract: This disclosure relates to immunogenic peptides that are specific to B-cell maturation antigen (BCMA) and Transmembrane activator and CAML interactor (TACI), and methods of use thereof.

Abstract: Disclosed are methods and compositions related to chimeric antigen receptors (CARs) that recognize Tissue Factor (TF). Specifically, disclosed are CARs that comprise fVII or a functional fragment thereof. Also disclosed are immune effector cells comprising the CARs disclosed herein.

Abstract: An object of the present invention is to provide an enhancer for endogenous T-cells or B-cells having a memory function and a malignant tumor recurrence inhibitor in order to continue to reject malignant tumor over a long period of time. An enhancer for T-cells or B-cells having a memory function in an administration subject, comprising a nucleic acid delivery vehicle, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding chemokine (C-C motif) ligand 19 (CCL19), and an inducer for inducing a memory function in T-cells or B-cells in an administration subject, are prepared. Also, a malignant tumor recurrence inhibitor comprising a nucleic acid delivery vehicle, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding CCL19, is prepared.

Abstract: Provided herein are methods and articles of manufacture for use with cell therapy for the treatment of diseases or conditions, e.g., cancer, including for predicting and treating a toxicity. In some embodiments, the toxicity is related to cytokine release syndrome (CRS). The methods generally involve assessing a change in a factor indicative of tumor burden prior to administration of a cell therapy in a subject that is associated with and/or correlate to a risk of developing toxicity. In some aspects, the methods can be used to determine if the subject is at risk or likely at risk for developing a toxicity following administration of the cell therapy. Also provided are methods for treating a subject having a disease or condition, in some cases involving administration of the cell therapy, based on assessment of risk of developing a toxicity following administration of the therapy. Also provided herein are reagents and kits for performing the methods.

Abstract: Immune cells engineered to reduce or eliminate expression and/or the function of a NR4A, TOX, NR4A and a TOX or NR4A and a TOX with increasing expression of IL-21 in said cells are disclosed. Also cells engineered to inhibit expression and/or function of NFAT/AP-1 pathway are provided. Disclosed cells are T and NK cells. It can be expanded to create homogeneous or heterogenous cell populations and/or combined with pharmaceutically acceptable carriers. It can be CAR cells. Methods to induce an immune response and treat conditions requiring selective immunotherapy, comprising contacting a target cell with the cells or compositions as described herein. The contacting can be performed in vitro or in vivo, thereby providing immunotherapy to a subject. Additionally presented herein are methods of producing such engineered cells. Kits containing the materials for making and using the cells are also provided.

Abstract: Compositions and methods are provided for classification and treatment of MYC-driven cancers, i.e. causally dependent on MYC as a result of, over-expression of MYC, constitutive expression of MYC, chromosomal translocation resulting in overactive MYC, and the like. Specifically, the methods comprising determining the MYC status of the cancer, and in a cancer that is determined to be driven by MYC activation, administering a composition of an effective dose of one or both of activated natural killer (NK) cells and a type 1 interferon.

Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.

Abstract: The present invention relates to augmenting the effects of adoptive T cell therapy, such as TVAX Immunotherapy, using adjunct treatment with an oncolytic virus, such as a vaccinia virus, to treat various types of cancer or other proliferative disorders. Immunomodulatory compounds can be used to further augment to effects of the therapy.

Abstract: The present invention discloses a chimeric antigen receptor (CAR) comprising an antigen binding domain specific for BDCA2, a population of engineered cells expressing said CAR and a pharmaceutical composition thereof. Said engineered cells are for treatment of cancer in a subject, wherein the cancerous cells of said cancer express BDCA2 such as Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

Abstract: The present invention provides a regulatory T (Treg) cell expressing an antigen chimeric receptor (CAR) comprising a) at least one antigen binding domain, b) a transmembrane domain, and c) a cytoplasmic signaling domain comprising at least one primary cytoplasmic signaling domain and at least the co-stimulatory signaling domain of CD137, wherein said antigen binding domain specifically binds an antigen that is expressed on the surface of a target cell or a tag of a tagged polypeptide that binds to an antigen expressed on the surface of a target cell or a soluble antigen. Compositions comprising said Treg cells, and methods of enrichment and analysis of activated Tregs that express said CAR are also disclosed.

Abstract: The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in and a method for preventing or treating migraine in a human.

Abstract: The present invention relates to a pharmaceutical composition for treating cardiac hypertrophy, comprising at least a stem cell and a pharmaceutically acceptable vehicle, wherein the stem cell is prepared by a pretreatment reaction of reacting with an n-butylidenephthalide (BP). The pharmaceutical composition of the present invention can be administered into a body of a hypertensive patient by remote intramuscular injection, so as to reduce superoxide content in the myocardium, increase STAT3 activity, and increase the content of M2 macrophages that promote inflammation resolution, and further effectively treat the symptoms of cardiac hypertrophy caused by hypertension.

Abstract: The present disclosure relates to a composition for various applications, which is capable of effectively preventing, ameliorating or treating lupus using a secretome derived from mesenchymal stem cells. The secretome derived from mesenchymal stem cells according to the present disclosure may significantly decrease mortality and the amount of proteinuria, and may increase body weight, decrease the expression of serum creatinine, and inhibit glomerular, coronary and vascular damage in kidney tissue. Furthermore, the secretome may reduce the size of an enlarged spleen and reduce the number of splenocytes and CD4-positive T cells. In addition, the secretome may increase the expression of the anti-inflammatory cytokines IL-10 and TGF-?1 in serum, and decrease the expression of anti-dsDNA antibody.

Abstract: The disclosure relates to new compositions for the treatment of neuropathy. The compositions of the disclosure provide increased efficacy in the treatment of diabetic neuropathy when applied topically to diabetic ulcers.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative disease, containing, as active ingredients, cyclodextrin and stem cells in which VEGF is overexpressed. A combined treatment of cyclodextrin and stem cells in which VEGF is overexpressed has remarkable synergistic effects, with respect to therapeutic efficacy on the disease, such as a lifespan increase, mobility improvement, inhibition of neurogenic inflammation, inhibition of nerve cell apoptosis and inhibition of lipid accumulation in organs, including the brain, on a neurodegenerative disease model, thereby presenting a novel therapeutic strategy.

Abstract: Methods and mechanisms for treating and/or alleviating myotonic dystrophy type 1 (DM1 by editing the DMPK gene. Editing of the DMPK gene may take place in vivo, or may involve ex vivo correction followed by implantation of genome-corrected cells.

Abstract: Provided are methods for producing compositions comprising a population of cardiomyocytes enriched for or substantially devoid of sinoatrial node-like pacemaker cardiomyocytes (SANLCM) from human pluripotent stem cells (hPSCs), and methods of use thereof.

Abstract: Wound treatment compositions obtained from cadaveric tissues are provided. Methods of processing such tissues to form wound treatment compositions are provided. Methods of treating a wound are also provided.

Abstract: Visco-supplement compositions derived from a transcellular fluid, such as human amniotic fluid, human aqueous humor fluid, or human vitreous fluid are described. Also described are methods for treating inflammatory conditions of the musculoskeletal system, such as joint inflammation, and methods of lubricating a joint using the described visco-supplement compositions.

Abstract: Provided is a composition comprising Bacteroides fragilis. The composition is used for enhancing the immune function of the T cells in a body, or for preventing and/or treating tumors.

Abstract: The invention provides compositions comprising one or more bacterial strains for treating preventing diarrhea and/or constipation.

Abstract: The invention provides compositions comprising one or more bacterial strains for use in a method of reducing the level of Enterobacteriaceae in the gastrointestinal tract.

Abstract: Methods of inhibiting or reducing tumor metabolism and growth are disclosed. A composition containing oxygen scavenging membrane fragments and anaerobe bacteria is injected into a tumor to interfere with tumor growth and metabolism, leading to tumor necrosis. The composition may also contain a cryoprotectant, which permits the composition to be stored at sub-zero temperatures without freezing.

Abstract: The present invention relates to compositions and methods for reducing the carriage of antibiotic resistance genes.

Abstract: A method for the prevention or treatment of infections contracted by newborns of livestock mammals, which includes applying a composition that includes a mixture of bacterial strains to the perineum and/or the teat(s) of female livestock mammal that is going to give birth or has given birth to the newborn livestock mammals. Also, a kit for preventing digestive, respiratory or other infections in newborn livestock mammals, which includes at least one composition and at least one application element for applying the composition to the perineum and/or to the teats of the female livestock mammals.

Abstract: An object of the present invention is to provide a composition for promoting fibroblast proliferation and/or a composition for promoting hyaluronic acid synthase gene expression. The present invention provides a composition for promoting fibroblast proliferation and/or a composition for promoting hyaluronic acid synthase gene expression, the compositions each comprising Lactobacillus plantarum L-137.

Abstract: The present invention refers to a composition including a fermented supernatant of Lactobacillus casei or paracasei species The species is characterized by having in its DNA genome at least one DNA sequence essentially identical to one of the sequences selected from the group consisting of: SEQ ID No 1 to 5, and proper diluents and/or carriers and/or excipients. The compositions can be used in the treatment and/or prevention of skin and/or dermatological diseases related to inflammation, allergic reactions, contact hypersensitivity reactions and intolerance, excessive sebaceous secretion, exfoliation or microbial dysbiosis, preferably of the epidermis.

Abstract: Methods and compositions for treating primary hepatic cancers and/or secondary hepatic cancers using a combination of talimogene laherparepvec and pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof are provided.

Abstract: New extracts of halophytes and psammophilous plants are suggested, obtainable by treating said microalgae and plants with a solvent selected from the group consisting of C1-C4 aliphatic alcohols, ethyl acetate, water or their mixtures, removing the dissolved extracts from the residues and recovering the pure extracts from the solvent. The extracts show excellent activity as regulators of the metabolism of human sebaceous glands.

Abstract: An anti-inflammatory composition of Candida albicans which comprises heat-killed Candida albicans in combination with a neuroprotective supplement. The composition provides a method of stimulating a host immune response capable of reducing a total Candida albicans yeast load below the threshold necessary for the host to keep the Candida albicans yeast and related yeast species in a commensal, non-invasive state. This effect inhibits or prevents chronic inflammation related to invasive Candida genus and allows the composition to be useful for the prevention, prophylaxis, and/or treatment of chronic inflammatory conditions, as well as diseases and disorders of the central nervous system resulting from high L-glutamate levels due to Candida albicans in the gastrointestinal system.